Analytical Data
-
Gene name
ATG5
- Application
-
Alternative Names
ASP; APG5; APG5L; hAPG5; Apoptosis-specific protein; Autophagy protein 5
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H1Y0
-
Expression Region
Met1~Asp275
-
Molecular Weight
36kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of ATG5 recombinant protein has gained significant importance in the field of cellular biology and medicine due to its critical role in autophagy, a fundamental cellular degradation process that maintains cellular homeostasis and regulates various physiological functions. Autophagy is essential for the removal of damaged organelles, misfolded proteins, and pathogens, thus influencing cell survival, differentiation, and response to stress. ATG5 is a key protein in the autophagy pathway, functioning as a crucial mediator in the formation of autophagosomes, the structures responsible for engulfing cellular debris. Disruption of ATG5 activity has been implicated in various diseases, including neurodegenerative disorders, cancer, and infectious diseases, making it a target for therapeutic intervention. By studying the recombinant form of ATG5, researchers aim to elucidate its functional mechanisms and interactions within the autophagy machinery, paving the way for novel therapeutic strategies that could harness or modulate autophagic processes. Additionally, the generation of recombinant ATG5 allows for detailed biochemical studies and potential applications in drug development, as it can be used to screen for small molecules that could enhance or inhibit autophagy, offering insights into the complex regulatory networks that govern cellular health and disease. Thus, the exploration of ATG5 recombinant protein holds promise for advancing our understanding of autophagy and its implications in various pathologies, ultimately leading to innovative approaches in treating diseases associated with autophagic dysregulation.
